Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT ID: NCT05740566
Last Updated: 2026-01-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
509 participants
INTERVENTIONAL
2023-05-31
2028-03-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
NCT03319940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tarlatamab
Participants will receive tarlatamab as an intravenous (IV) infusion.
Tarlatamab
Tarlatamab will be administered as an IV infusion.
Standard of Care
Participants will receive treatment per local standard of care (SOC).
Lurbinectedin
Lurbinectedin will be administered per local SOC.
Topotecan
Topotecan will be administered per local SOC.
Amrubicin
Amrubicin will be administered per local SOC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarlatamab
Tarlatamab will be administered as an IV infusion.
Lurbinectedin
Lurbinectedin will be administered per local SOC.
Topotecan
Topotecan will be administered per local SOC.
Amrubicin
Amrubicin will be administered per local SOC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
* Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
* Participants who progressed or recurred following 1 platinum-based regimen.
* Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
* Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
* Minimum life expectancy of 12 weeks.
* Adequate organ function.
Exclusion Criteria
* Symptomatic central nervous system (CNS) metastases with exceptions defined in the protocol.
* Diagnosis or evidence of leptomeningeal disease.
* Prior history of immune checkpoint inhibitors resulting in events defined in the protocol.
* Other Medical Conditions
* Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy.
* History of solid organ transplantation.
* History of other malignancy within the past 2 years, with exceptions defined in the protocol.
* Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 12 months prior to first dose of study treatment.
* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months prior to first dose of study treatment.
* Presence or history of viral infection based on criteria per protocol.
* Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to first dose of study treatment.
* Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment.
* Evidence of interstitial lung disease or active, non-infectious pneumonitis.
* Prior/Concomitant Therapy
* Prior therapy with tarlatamab or any of the standard of care chemotherapy included as part of this trial or participation in any tarlatamab or any other DLL3 targeted agent clinical trial.
* Prior therapy with any selective inhibitor of the DLL3 pathway.
* Participant received more than one prior systemic therapy regimen for SCLC.
* Prior anti-cancer therapy within 21 days prior to first dose of study treatment with exceptions defined in protocol.
* Current anti-cancer therapy such as chemotherapy, immunotherapy, or targeted therapy with exceptions.
* Use of herbal or prescription/non-prescription medications known to inhibit membrane transporters P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) within 7 days prior to the first dose of study treatment.
* Use of herbal or prescription/non-prescription medications known to be moderate or strong inhibitors of cytochrome P450 3A (CYP3A) enzymes within 7 days prior to the first dose of study treatment.
* Use of herbal or prescription/non-prescription medications known to be moderate or strong inducers of CYP3A enzymes within 28 days prior to first dose of study treatment.
* Participants who have reached the limit dose of prior treatment with cardiotoxic drugs.
* Major surgical procedures within 28 days prior to first dose of study treatment.
* Live and live-attenuated vaccines within 14 days prior to the start of study treatment.
* Inactive vaccines and live viral non-replicating vaccines within 3 days prior to the first dose of study treatment.
* Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
* Diagnostic Assessments
* Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, with exceptions defined in the protocol.
* Other Exclusions
* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
* Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab.
* Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of tarlatamab.
* Female participants of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test.
* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab.
* Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of tarlatamab.
* Contraception requirements for male and female participants receiving SOC therapies are based on regional prescribing information.
* Breastfeeding restrictions for female participants receiving SOC therapies are based on regional prescribing information.
* Participant has known sensitivity or is contraindicated to any of the products or components to be administered during dosing.
* Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures.
* History or evidence of any other clinically significant disorder, condition or disease determined by the investigator or Amgen physician that would pose a risk to the subject safety or interfere with the study evaluation..
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Alaska Oncology and Hematology
Anchorage, Alaska, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
University of California Los Angeles
Santa Monica, California, United States
Northwestern University
Chicago, Illinois, United States
University of Illinois Chicago
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
University of Iowa
Iowa City, Iowa, United States
Pikeville Medical Center
Pikeville, Kentucky, United States
Our Lady of the Lake Cancer Institute
Baton Rouge, Louisiana, United States
Trinity Health Saint Joseph Mercy Ann Arbor
Ann Arbor, Michigan, United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
University of Missouri Health Care
Columbia, Missouri, United States
Summit Medical Group, Overlook Oncology Center
Summit, New Jersey, United States
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York, United States
Perlmutter Cancer Center at New York University Langone Hospital----Long Island
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Northport Veterans Affairs Medical Center
Northport, New York, United States
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota, United States
University of Tennessee Medical Center Knoxville
Knoxville, Tennessee, United States
Baptist Cancer Center
Memphis, Tennessee, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Swedish Cancer Institute Medical Oncology
Edmonds, Washington, United States
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Cemic
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Sociedad de Beneficencia Hospital Italiano
Córdoba, Córdoba Province, Argentina
Clinica Viedma
Viedma, Río Negro Province, Argentina
Sanatorio Parque SA
Rosario, Santa Fe Province, Argentina
Instituto Argentino de Diagnostico y Tratamiento IADT
Buenos Aires, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Liverpool Hospital
Liverpool, New South Wales, Australia
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Medizinische Universitaet Graz
Graz, , Austria
Universitaetsklinikum Krems
Krems, , Austria
Universitair Ziekenhuis Gent
Ghent, , Belgium
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, , Belgium
AZ Delta Campus Rumbeke
Roeselare, , Belgium
Vitaz campus Sint-Niklaas Moerland
Sint-Niklaas, , Belgium
Hospital Santa Izabel
Salvador, Estado de Bahia, Brazil
Instituto de Ensino e Pesquisa do Hospital da Bahia
Salvador, Estado de Bahia, Brazil
Liga Norte-Riograndense Contra O Cancer
Natal, Rio Grande do Norte, Brazil
Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Amor da Amazonia
Porto Velho, Rondônia, Brazil
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Beneficencia Portuguesa de Sao Paulo - Bp
São Paulo, São Paulo, Brazil
Oncologia Rede D Or
São Paulo, São Paulo, Brazil
Instituto Coi
Rio de Janeiro, , Brazil
Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp
São Paulo, , Brazil
London Health Sciences Centre
London, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Anhui Chest Hospital
Hefei, Anhui, China
Beijing Tongren Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Army Medical University, PLA
Chongqing, Chongqing Municipality, China
Army Special Medical Center of Peoples Liberation Army
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Jiangmen Central Hospital
Jiangmen, Guangdong, China
The 4th Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Subei Peoples Hospital
Yangzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
Jinan Central Hospital
Jinan, Shandong, China
Shandong Tumor Hospital
Jinan, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanxi Province Cancer Hospital
Taiyuan, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Beijing Chest Hospital, Capital Medical University
Beijing, , China
Fujian Cancer Hospital
Fuzhou, , China
Tianjin Peoples Hospital
Tianjin, , China
Weihai Municipal Hospital
Weihai, , China
Fakultni nemocnice Brno
Brno, , Czechia
Masarykuv onkologicky ustav
Brno, , Czechia
Fakultni nemocnice Olomouc
Olomouc, , Czechia
Nemocnice Agel Ostrava-Vitkovice as
Ostrava-Vitkovice, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Rigshospitalet
Copenhagen, , Denmark
Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon
Grenoble, , France
Centre Hospitalier Régional Universitaire de Lille - Institut Coeur Poumon
Lille, , France
Centre Hospitalier Regional Universitaire de Limoges - Hopital Dupuytren
Limoges, , France
Centre Leon Berard
Lyon, , France
Centre Hospitalier Universitaire Nord
Marseille, , France
Institut Curie
Paris, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, , France
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil
Strasbourg, , France
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
Toulouse, , France
Gustave Roussy
Villejuif, , France
Charite Universitaetsmedizin Berlin, Campus Virchow
Berlin, , Germany
Universitaetsklinikum Koeln
Cologne, , Germany
Universitaetsklinikum Dresden
Dresden, , Germany
Universitaetsklinikum Essen
Essen, , Germany
Asklepios Fachkliniken Muenchen Gauting
Gauting, , Germany
LungenClinic Grosshansdorf GmbH
Großhansdorf, , Germany
Robert-Bosch-Krankenhaus
Stuttgart, , Germany
Universitaetsklinikum Wuerzburg
Würzburg, , Germany
Saint Savas Hospital
Athens, , Greece
Henry Dunant Hospital Center
Athens, , Greece
Thoracic General Hospital Of Athens Sotiria
Athens, , Greece
Alexandra Hospital
Athens, , Greece
University Hospital of Heraklion
Heraklion - Crete, , Greece
Olympion Therapeftirio General Clinic Of Patras
Pátrai, , Greece
Saint Luke Hospital
Thessaloniki, , Greece
European Interbalkan Medical Center
Thessaloniki, , Greece
Semmelweis Egyetem
Budapest, , Hungary
Orszagos Koranyi Pulmonologiai Intezet
Budapest, , Hungary
Matrai Gyogyintezet
Gyöngyös, , Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, , Hungary
Komarom-Esztergom Varmegyei Szent Borbala Korhaz
Tatabánya, , Hungary
Reformatus Pulmonologiai Centrum
Törökbálint, , Hungary
Beaumont Hospital
Dublin, , Ireland
Rambam Medical Center
Haifa, , Israel
Hadassah Ein-Kerem Medical Center
Jerusalem, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Humanitas Gavazzeni
Bergamo, , Italy
Azienda Ospedaliera Universitaria Renato Dulbecco
Catanzaro, , Italy
Ospedale Policlinico San Martino IRCCS
Genova, , Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola (FC), , Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga
Orbassano, , Italy
Azienda Ospedaliera San Giovanni Addolorata
Roma, , Italy
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
Kurume University Hospital
Kurume-shi, Fukuoka, Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, Japan
Hyogo Cancer Center
Akashi-shi, Hyōgo, Japan
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Sendai Kousei Hospital
Sendai, Miyagi, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
Kansai Medical University Hospital
Hirakata-shi, Osaka, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Kindai University Hospital
Osakasayama-shi, Osaka, Japan
Saitama Medical University International Medical Center
Hidaka-Shi, Saitama, Japan
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan
Wakayama Medical University Hospital
Wakayama, Wakayama, Japan
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan
Kuantan, Pahang, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
coi Centro Oncologico Internacional sapi de cv
Tlajomulco de Zúñiga, Jalisco, Mexico
Health Pharma Professional Research SA de CV
Mexico City, Mexico City, Mexico
Oncare
Mexico City, Mexico City, Mexico
Universitair Medisch Centrum Groningen
Groningen, , Netherlands
Leids Universitair Medisch Centrum
Leiden, , Netherlands
Erasmus Medisch Centrum
Rotterdam, , Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, , Netherlands
Centrum Pulmonologii i Torakochirurgii w Bystrej
Bystra, , Poland
Szpital Specjalistyczny imienia Ludwika Rydygiera w Krakowie Sp zoo
Krakow, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow
Poznan, , Poland
Hospital da Luz, SA
Lisbon, , Portugal
Hospital Cuf Descobertas
Lisbon, , Portugal
Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano
Matosinhos Municipality, , Portugal
Hospital Cuf porto
Porto, , Portugal
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
Cluj-Napoca, , Romania
Centrul de Oncologie Sf Nectarie SRL
Craiova, , Romania
Institutul Regional de Oncologie Iasi
Iași, , Romania
SC Oncomed SRL
Timișoara, , Romania
National Cancer Centre Singapore
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Chungbuk National University Hospital
Cheongju Chungbuk, , South Korea
National Cancer Center
Goyang-si Gyeonggi-do, , South Korea
Gachon University Gil Hospital
Incheon, , South Korea
Gyeongsang National University Hospital
Jinju, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, , South Korea
Severance Hospital Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
The Catholic University of Korea Seoul St Marys Hospital
Seoul, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Hospital Regional Universitario de Malaga
Málaga, Andalusia, Spain
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Aragon, Spain
Hospital del Mar
Barcelona, Catalonia, Spain
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Complexo Hospitalario Universitario A Coruna Hospital Teresa Herrera
A Coruña, Galicia, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Kantonsspital Graubuenden
Chur, , Switzerland
Freiburg Spital
Fribourg, , Switzerland
Hopitaux universitaires de Geneve
Geneva, , Switzerland
Kantonsspital Sankt Gallen
Sankt Gallen, , Switzerland
Kantonsspital Winterthur
Winterthur, , Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Veterans General Hospital - Taichung
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Memorial Ankara Hastanesi
Ankara, , Turkey (Türkiye)
Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi
Ankara, , Turkey (Türkiye)
Ankara Bilkent Sehir Hastanesi
Ankara, , Turkey (Türkiye)
Pamukkale Universitesi Tip Fakultesi Hastanesi
Denizli, , Turkey (Türkiye)
Bagcilar Medipol Mega Universite Hastanesi
Istanbul, , Turkey (Türkiye)
Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
Istanbul, , Turkey (Türkiye)
Ege Universitesi Tip Fakultesi Hastanesi
Izmir, , Turkey (Türkiye)
Izmir Ekonomi Universitesi Medical Point Hastanesi
Izmir, , Turkey (Türkiye)
Inonu Universitesi Turgut Ozal Tip Merkezi
Malatya, , Turkey (Türkiye)
University College London Hospital
London, , United Kingdom
Guys Hospital
London, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gumus M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazieres J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025 Jul 24;393(4):349-361. doi: 10.1056/NEJMoa2502099. Epub 2025 Jun 2.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. Future Oncol. 2024 Dec;20(40):3355-3364. doi: 10.1080/14796694.2024.2402152. Epub 2024 Nov 12.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20210004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.